9.10 Industrial Applications of Organocatalysis

Comprehensive Chirality

Volumn 9, Issue , 2012, Pages 228-252

  Bulger, P G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asymmetric; Enantioselective; Industrial; Industry; Kilogram; Large scale; Manufacturing; Organocatalysis; Pharmaceutical; Phase transfer catalysis

Indexed keywords

EID: 84902415484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-095167-6.00911-3     Document Type: Chapter

References (167)

1. Asymmetric Catalysis on Scale: Challenges, Approaches and Solutions 2010, Wiley-VCH, Weinheim, p580. 2nd ed. H.-U. Blaser, H.-J. Federsel (Eds.).
2. Gröger H. Ernst Schering Found. Symp. Proc. 2007, 2:141-158. For previous excellent reviews of large-scale applications of organocatalysis, see:.
3. Berkessel A., Gröger H. Asymmetric Organocatalysis 2005, Wiley-VCH, Weinheim, pp 393-408.
4. Farina V., Reeves J.T., Senanayake C.H., Song J.J. Chem. Rev. 2006, 106(7):2734-2793.
5. O'Brien M.K., Vanasse B. Curr. Opinion Drug Discovery 2000, 3(6):793-806.
6. Carey J.S., Laffan D., Thomson C., Williams M.T. Org. Biomol. Chem. 2006, 4(12):2337-2347.
7. Butters M., Catterick D., Craig A., et al. Chem. Rev. 2006, 106(7):3002-3027.
8. Zhang T.Y. Chem. Rev. 2006, 106(7):2583-2595.
9. Federsel H.-J. Acc. Chem. Res. 2009, 42(5):671-680.
10. Hawkins J.M., Watson T.J.N. Angew. Chem. Int. Ed. 2004, 43(25):3224-3228.
11. Blaser H.-U., Pugin B., Spindler F. J. Mol. Catal. A: Chem. 2005, 231(1/2):1-20.
12. Federsel H.-J. Drug Discovery Today 2006, 11(1/2):966-974.
13. Kola I., Landis J. Nat. Rev. Drug Discovery 2004, 3(8):711-715.
14. Rubin A.E., Tummala S., Both D.A., Wang C., Delaney E.J. Chem. Rev. 2006, 106(7):2794-2810.
15. Shultz C.S., Krska S.W. Acc. Chem. Res. 2007, 40(12):1320-1326. For examples of high-throughput screening applied to asymmetric hydrogenation reactions, see:.
16. Hansen K.B., Hsiao Y., Xu F., et al. J. Am. Chem. Soc. 2009, 131(25):8798-8804. For a dramatic example of the reduction in waste generation per kilogram of API produced though optimization of a route based on asymmetric catalysis, see:.
17. List B. Angew. Chem. Int. Ed. 2010, 49(10):1730-1734. For reviews of the historical development of organocatalysis, see:.
18. Berkessel A., Gröger H. Asymmetric Organocatalysis 2005, Wiley-VCH, Weinheim, pp 1-8.
19. Ahrendt K.A., Borths C.J., MacMillan D.W.C. J. Am. Chem. Soc. 2000, 122(17):4243-4244. The term 'organocatalysis' was only coined in 2000; see:.
20. MacMillan D.W.C. Nature 2008, 455:304-308.
21. Bertelsen S., Jørgensen K.A. Chem. Soc. Rev. 2009, 38(8):2178-2189. This rapid development has been called the 'gold rush' and 'golden age' of organocatalysis; see:.
22. Dalko P.I., Moisan L. Angew. Chem. Int. Ed. 2004, 43(39):5138-5175.
23. Dondoni A., Massi A. Angew. Chem. Int. Ed. 2008, 47(25):4638-4660.
24. Enantioselective Organocatalysis: Reactions and Experimental Procedures 2007, For selected examples of other monographs covering organocatalysis outside of this reference work, see:, Wiley-VCH, Weinheim, p 559. P.I. Dalko (Ed.).
25. Berkessel A., Gröger H. Asymmetric Organocatalysis 2005, Wiley-VCH, Weinheim, p 440.
26. List, B.; A thematic issue of Chem. Rev. 2007, 107(12):5413-5883.
27. Sierra M.A., de la Torre M.C. Angew. Chem. Int. Ed. 2000, 39(9):1538-1559. For an academic perspective on 'Dead Ends and Detours', see:.
28. Rowe S.M. Org. Process Res. Dev. 2002, 6(6):877-883.
29. Thommen M., Blaser H.-U. Chem. Today 2003, 21(12):6-8. For a discussion of various possible licensing strategies, see:.
30. Johnson N.B., Lennon I.C., Moran P.H., Ramsden J.A. Acc. Chem. Res. 2007, 40(12):1291-1299.
31. European Medicines Agency Site. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003469.pdf.
32. Gleeson O., Tekoriute R., Gun'ko Y.K., Connon S.J. Chem. Eur. J. 2009, 15(23):5669-5673. For examples, see:.
33. Selkälä S.A., Tois J., Pihko P.M., Koskinen A.M.P. Adv. Synth. Catal. 2002, 344(9):941-945.
34. Sakthivel K., Notz W., Bui T., Barbas C.F. J. Am. Chem. Soc. 2001, 123(22):5260-5267.
35. Sigman M.S., Vachal P., Jacobsen E.N. Angew. Chem. Int. Ed. 2000, 39(7):1279-1281.
36. Pugin B., Blaser H.-U. Topics Catal. 2010, 53(13-14):953-962.
37. Savile C.K., Janey J.M., Mundorff E.C., et al. Science 2010, 329:305-309. This sweeping generalization holds true for most catalytic asymmetric reactions. The main exceptions are found in several types of enzymatic transformations, which with appropriate substrates can generate stereogenic centers with undetectable levels of the undesired enantiomer. For an example, see:.
38. Chen A.M., Wang Y., Wenslow R.M. Org. Process Res. Dev. 2008, 12(2):271-281.
39. Wang Y., Chen A.M. Org. Process Res. Dev. 2008, 12(2):282-290.
40. Maeda K., Miller R.A., Szumigala R.H., et al. Tetrahedron Lett. 2005, 46(9):1545-1549. For selected examples, see: Phase-transfer catalyzed alkylation:.
41. Lee T.B.K., Wong G.S.K. J. Org. Chem. 1991, 56(2):872-875. Aza-Michael reaction:.
42. Lin Q., Meloni D., Pan Y., et al. Org. Lett. 2009, 11(9):1999-2002.
43. Robichaud J., Tremblay F. Org. Lett. 2006, 8(4):597-600. Friedel-Crafts alkylation:.
44. King H.D., Meng Z., Denhart D., et al. Org. Lett. 2005, 7(16):3437-3440. Epoxidation:.
45. Flisak J.R., Gombatz K.J., Holmes M.M., et al. J. Med. Chem. 1993, 58(23):6247-6254.
46. Seki M. Synlett 2008, 2:164-176.
47. Tsogoeva S.B., Wöltinger J., Jost C., et al. Synlett 2002, 5:707-710.
48. Geller T., Gerlach A., Krüger C.M., Militzer H.-C. J. Mol. Catal. A: Chem. 2006, 251(1-2):71-77.
49. Asymmetric Phase Transfer Catalysis 2008, Wiley-VCH, Weinheim, p 214. K. Maruoka (Ed.).
50. Halpern M.E. Process Chem. Pharmaceut. Ind. 1999, 283-298. For an excellent summary of the benefits and challenges of applying PTC technology in the pharmaceutical industry, see:.
51. Marcelli A., Hiemstra H. Synthesis 2010, 8:1229-1279. For reviews of Cinchona alkaloids in asymmetric organocatalysis, see:.
52. Cinchona Alkaloids in Synthesis & Catalysis: Ligands, Immobilization and Organocatalysis 2010, Wiley-VCH, Weinheim, p 546. C.E. Song (Ed.).
53. Dolling U.-H., Davis P., Grabowski E.J.J. J. Am. Chem. Soc. 1984, 106(2):446-447.
54. Hughes D.H., Dolling U.-H., Ryan K.M., Schoenewaldt E.F., Grabowski E.J.J. J. Org. Chem. 1987, 52(21):4745-4752.
55. deSolms S.J., Woltersdorf O.W., Cragoe E.J., Watson L.S., Fanelli G.M. J. Med. Chem. 1978, 21(5):437-443.
56. Corey E.J., Noe.M.C. Org. Synth. 2003, 80:38-45.
57. Wilkening, R. R.; Fried, A.; Parker, D. L. Jr. (Merck & Co., Inc.) Synthesis of 1,5-disubstituted-2-hydroxygibbatetraen-6-ones from indan-1-one derivatives. World Pat. Appl. 50,399, 2006; Chem. Abstr.2006, 144, 468334.
58. Scott J.P., Ashwood M.S., Brands K.M.J., et al. Org.Process Res. Dev. 2008, 12(4):723-730.
59. Conn R.S.E., Lovell A.V., Karady S., Weinstock L.M. J. Org. Chem. 1986, 51(24):4710-4711. For earlier studies on the conjugate addition of indanones to MVK using Cinchona alkaloid-derived catalysts, see;.
60. Huffman M.A., Rosen J.D., Farr R.N., Lynch J.E. Tetrahedron 2007, 63(21):4459-4463.
61. Bhattacharya A., Dolling U.-H., Grabowski E.J.J., et al. Angew. Chem. Int. Ed. 1986, 25(5):476-477.
62. O'Donnell M.J., Bennett W.D., Wu.S. J. Am. Chem. Soc. 1989, 111(6):2353-2355.
63. O'Donnell M.J., Wu S., Huffman J.C. Tetrahedron 1994, 50(15):4507-4518.
64. O'Donnell M.J. Acc. Chem. Res. 2004, 37(8):506-517.
65. Lygo B., Wainwright P.G. Tetrahedron Lett. 1997, 38(49):8595-8598. For selected examples, see:.
66. Corey E.J., Xu F., Noe M.C. J. Am. Chem. Soc. 1997, 119(50):12414-12415.
67. Ooi T., Kameda M., Marouka K. J. Am. Chem. Soc. 1999, 121(27):6519-6520.
68. Ooi T., Maruoka K. Angew. Chem Int. Ed. 2007, 46(23):4222-4266.
69. Hashimoto T., Maruoka K. Chem. Rev. 2007, 107(12):5656-5682.
70. Patterson D.E., Xie S., Jones L.A., et al. Org. Process Res. Dev. 2007, 11(3):624-627.
71. Evans D.A., Britton T.C. J. Am. Chem. Soc. 1987, 109(22):6881-6883.
72. Trost B.M. Angew. Chem. Int. Ed. 1995, 34(3):259-281.
73. Trost B.M. Science 1991, 254:1471-1477.
74. Lygo B., Allbutt B. Synlett 2004, 2:326-328. The bulky benzophenone imine is required both to enhance the acidity of the methylene protons in the starting material 33 and sterically shield the resulting alkylation product 35 from epimerization by another deprotonation event. The tert-butyl ester protecting group is most commonly used due to its stability towards the basic conditions, though smaller groups can also be employed; see:.
75. Ooi T., Uematsu Y., Maruoka K. Tetrahedron Lett. 2004, 45(8):1675-1678.
76. Hinrichsen H., Benhamou Y., Wedemeyer H., et al. Gastroenterology 2004, 127(5):1347-1355.
77. Liverton N.J., Holloway M.K., McCauley J.A., et al. J. Am. Chem. Soc. 2008, 130(14):4607-4609.
78. Beaulieu P.L., Gillard J., Bailey M.D., et al. J. Org. Chem. 2005, 70(15):5869-5879.
79. Belyk K.M., Xiang B., Bulger P.G., et al. Org. Process Res. Dev. 2010, 14(3):692-700.
80. Fox M.E., Lennon I.C., Farina V. Tetrahedron Lett. 2007, 48(6):945-948.
81. Moreau B., Charette A.B. J. Am. Chem. Soc. 2005, 127(51):18014-18015.
82. Pei T., Tellers D.M., Streckfuss E.C., Chen C., Davies I.W. Tetrahedron 2009, 65(16):3285-3291. For examples of applying this technique to reaction screening and parallel synthesis, see:, and references therein.
83. Kitamura M., Shirakawa S., Maruoka K. Angew. Chem. Int. Ed. 2005, 44(10):1549-1551.
84. Seki M., Yamada S., Kuroda T., Imashiro R., Shimizu T. Synthesis 2000, 12:1677-1680.
85. Jiang X., Gong B., Prasad K., Repič O. Org. Process Res. Dev. 2008, 12(6):1164-1169.
86. Hinterding K., Cottens S., Albert R., et al. Synthesis 2003, 11:1667-1670.
87. Xu F., Corley E., Zacuto M., et al. J. Org. Chem. 2010, 75(5):1343-1353.
88. Edmonson S.D., Mastracchio A., Cox J.M., et al. Bioorg. Med. Chem. Lett. 2009, 19(15):4097-4101.
89. Zhu Q., Huang H., Shi D., Shen Z., Xia S. Org. Lett. 2009, 11(20):4539-4549. For selected examples, see:.
90. Hynes P.S., Stupple P.A., Dixon D.J. Org. Lett. 2008, 10(7):1389-1391.
91. Okino T., Hoashi Y., Furukawa T., Xu X., Takemoto Y. J Am. Chem. Soc. 2005, 127(1):119-125.
92. Evans D.A., Seidel D. J. Am. Chem. Soc. 2005, 127(28):9958-9959. For a selected example, see:.
93. Li H., Wang Y., Tang L., Deng L. J. Am. Chem. Soc. 2004, 126(32):9906-9907.
94. List B., Lerner R.A., Barbas C.F. J. Am. Chem. Soc. 2000, 122(10):2395-2396.
95. Xu F., Zacuto M., Yoshikawa N., et al. J. Org. Chem. 2010, 75(22):7829-7841.
96. Gotoh H., Ishikawa H., Hayashi Y. Org. Lett. 2007, 9(25):5307-5309.
97. Palomo C., Landa A., Mieglo A., et al. Angew. Chem. Int. Ed. 2007, 46(44):8431-8435.
98. Zu L., Xie H., Li H., Wang J., Wang W. Adv. Synth. Catal. 2007, 349(17-18):2660-2664.
99. Wang Y., Li P., Liang X., Zhang T., Ye J. Chem. Commun. 2008, 10:1232-1234.
100. Marigo M., Wabnitz T.C., Fielenbach D., Jørgensen K.A. Angew. Chem. Int. Ed. 2005, 44(5):794-797.
101. Hayashi Y., Gotoh H., Hayashi T., Shoji M. Angew. Chem. Int. Ed. 2005, 44(27):4212-4215.
102. Eder U., Sauer G., Weichert R. Angew. Chem. Int. Ed. 1971, 10(7):496-497.
103. Hajos Z.G., Parrish D.R. J. Org. Chem. 1974, 39(12):1615-1621.
104. List B. Tetrahedron 2002, 58(28):5573-5590. For a more in-depth discussion of the Hajos-Parrish-Eder-Sauer-Wiechert reaction, see:.
105. Janey J.M., Hsiao Y., Armstrong J.D. J. Org. Chem. 2006, 71(1):390-392.
106. Berkessel A., Gröger H. Asymmetric Organocatalysis 2005, Wiley-VCH, Weinheim, pp 347-392.
107. Keen S.P., Cowden C.J., Bishop B.C., et al. J. Org. Chem. 2005, 70(5):1771-1779.
108. Chen Y., Tian S.-K., Deng L. J. Am. Chem. Soc. 2000, 122(39):9542-9543. For a studies on the mechanism of ring-opening using these catalysts, see:.
109. Li H., Liu X., Wu F., Tang L., Deng L. Proc. Nat. Acad. Sci. 2010, 107(48), 20625-20629.
110. Bolm C., Gerlach A., Dinter C.L. Synlett 1999, (2):195-196.
111. Bolm C., Schiffers I., Dinter C.L., Gerlach A. J. Org. Chem. 2000, 65(21):6984-6991.
112. Yue T.-Y., McLeod D.D., Albertson K.B., et al. Org. Process Res. Dev. 2006, 10(2):262-271.
113. De Lucca G.V., Kim U.T., Vargo B.J., et al. J Med. Chem. 2005, 48(6):2194-2211.
114. Mittendorf J., Benet-Buchholz J., Fey P., Mohrs K.-H. Synthesis 2003, 1:136-140.
115. Mittendorf, J.; Arold, H.; Fey, P.; et al. (Bayer AG) Enantioselective Process for the Preparation of High-enantiomeric-purity Cyclopentane-β-amino Acids and Cyclopentene-β-amino acids. Ger. Offen. DE 4400749, 1995.
116. Fülöp F. Chem. Rev. 2001, 101(7):2181-2204.
117. Ishii Y., Fujimoto R., Mikami M., et al. Org. Process Res. Dev. 2007, 11(3):609-615.
118. Buckley J., Webb R.L., Laird T., Ward R.J. Chem. Eng. News 1982, 60(28):5.
119. Peschiulli A., Gun'ko Y., Connon S.J. J. Org. Chem. 2008, 73(6):2454-2457.
120. Huang X., Broadbent S., Dvorak C., Zhao S.-H. Org. Process Res. Dev. 2010, 14(3):612-616.
121. Huang X., Zhu J., Broadbent S. Tetrahedron Lett. 2010, 51(12):1554-1557.
122. Gunosewoyo H., Coster M.J., Kassiou M. Curr. Med. Chem. 2007, 14(14):1505-1523. See, and references therein.
123. Hoffmann-Emery F., Hilpert H., Scalone M., Waldmeier P. J. Org. Chem. 2006, 71(5):2000-2008.
124. Vakulya B., Varga S., Csámpai A., Soós T. Org. Lett. 2005, 7(10):1967-1969.
125. Constable D.J.C., Jimenez-Gonzalez C., Henderson R.K. Org. Process Res. Dev. 2007, 11(1):133-137.
126. Gani R., Jimenez-Gonzalez C., ten Kate A., et al. Chem. Eng. 2006, 113(3):30-43.
127. Oh S.H., Rho H.S., Lee J.W., et al. Angew. Chem. Int. Ed. 2008, 47(41):7872-7875.
128. Robinson D.I. Org. Process Res. Dev. 2010, 14(4):946-959. The epoxide group is a structural alert for genotoxicity though, once properly evaluated, the potential risks associated with its use are often minimal. In fact, epoxides are present in a number of marketed drugs and other agents, including food additives. See:.
129. Snodin D.J. Org. Process Res. Dev. 2010, 14(4):960-976.
130. Axerio-Cilies U., Castañeda I.P., Mirza A., Reynisson J. Eur. J. Med. Chem. 2009, 44(3):1128-1134.
131. Wang Z.-X., Tu Y., Frohn M., Zhang J.-R., Shi.Y. J. Am. Chem. Soc. 1997, 119(46):11224-11235.
132. Tu Y., Wang Z.-X., Shi Y. J. Am. Chem. Soc. 1996, 118(40):9806-9807.
133. Frohn M., Shi Y. Synthesis 2000, 14:1979-2000.
134. Ager D.J., Anderson K., Oblinger E., Shi Y., VanderRoest J. Org. Process Res. Dev. 2007, 11(1):44-51.
135. Huff J.R. J. Med. Chem. 1991, 34(8):2305-2314.
136. Greenlee W.J. Med. Res. Rev. 1990, 10(2):173-236.
137. Urban F.J., Jasys V.J. Org. Process Res. Dev. 2004, 8(2):169-175.
138. Tu Y., Frohn M., Wang Z.-X., Shi Y. Org. Synth. 2003, 80:1-8.
139. Corey E.J., Bakshi R.K., Shibata S. J. Am. Chem. Soc. 1987, 109(18):5551-5553.
140. Itsuno S., Sakurai Y., Ito K., Hirao A., Nakahama S. Bull. Chem. Soc. Jpn. 1987, 60(1):395-396.
141. Jones T.K., Mohan J.J., Xavier L.C., et al. J. Org. Chem. 1991, 56(2):763-769.
142. Corey E.J., Helal C.J. Angew. Chem. Int. Ed. 1998, 37(15):1986-2012.
143. Itsuno S. Org. React. 1998, 52:395-576.
144. Burkhardt E.R., Matos K. Chem. Rev. 2006, 106(7):2617-2650.
145. Deloux L., Srebnik M. Chem. Rev. 1993, 93(2):763-784.
146. Wallbaum S., Martens J. Tetrahedron: Asymmetry 1992, 3(12):1475-1504.
147. Li D.R., He A., Falck J.R. Org. Lett. 2010, 12(8):1756-1759. For selected examples, see:.
148. Zhou L., Wang Z., Wei S., Sun J. Chem. Commun. 2007, 28:2977-2979.
149. Procuranti B., Connon S.J. Chem. Commun. 2007, 14:1421-1423.
150. Fu X., McAllister T.L., Thiruvengadam T.K., Tann C.-H., Su D. Tetrahedron Lett. 2003, 44:801-804.
151. Salunkhe A.M., Burkhardt E.R. Tetrahedron Lett. 1997, 38(9):1523-1526.
152. Periasamy M., Kanth J.V.B., Prasad A.S.B. Tetrahedron 1994, 50(21):6411-6416.
153. Chung J.Y.L., Cvetovich R., Amato J., et al. J. Org. Chem. 2005, 70(9):3592-3601.
154. Hamada T., Torii T., Izawa K., Noyori R., Ikariya T. Org. Lett. 2002, 4(24):4373-4376.
155. Noyori R., Ohkuma T. Angew. Chem. Int. Ed. 2001, 40(1):40-73.
156. Wilkinson H.S., Tanoury G.J., Wald S.A., Senanayake C.H. Org. Process Res. Dev. 2002, 6(2):146-148. For other examples of oxazaborolidine-catalyzed reductions using DEANB 129 as stoichiometric reductant, see:.
157. Garrett C.E., Prasad K., Repič O., Blacklock T.J. Tetrahedron: Asymmetry 2002, 13(13):1347-1349.
158. Brands K.M.J., Payack J.F., Rosen J.D., et al. J. Am. Chem. Soc. 2003, 125(8):2129-2135.
159. Reichard G.A., Stengone C., Paliwal S., et al. Org. Lett. 2003, 5(23):4249-4251. Researchers at Schering-Plough have also reported the CBS reduction of ketone 132 to give alcohol 133 on multihundred gram scale. See:.
160. Hansen K.B., Chilenski J.R., Desmond R., et al. Tetrahedron: Asymmetry 2003, 14(22):3581-3587. (b) Reference 107.
161. Pollard D., Truppo M., Pollard J., Chen C., Moore J. Tetrahedron: Asymmetry 2006, 17(4):554-559.
162. Lewiecki E.M. Idrugs 2009, 12(12):799-809.
163. O'Shea P.D., Chen C., Gauvreau D., et al. J. Org. Chem. 2009, 74(4):1605-1610.
164. Gauthier J.Y., Chauret N., Cromlish W., et al. Bioorg. Med. Chem. Lett. 2008, 18(3):923-928. A previous approach the benzylic stereocenter in odanacatib 139 employed the diastereoselective aryllithium addition to an α-trifluoromethyl imine, though cryogenic temperatures (below -70°C) were required and the required aryllithium species was unstable to prolonged hold times. See:.
165. Roy A., Gosselin F., O'Shea P.D., Chen C. J. Org. Chem. 2006, 71(11):4320-4323.
166. Grondal C., Jeanty M., Enders D. Nat. Chem. 2010, 2(3):167-178.
167. Davies I.W., Welch C.J. Science 2009, 325:701-704.